Abu Dhabi-based AI investment firm MGX has joined a $2.1 billion Series B funding round for Isomorphic Labs, the artificial intelligence drug discovery company spun out of Google DeepMind, as the UAE continues expanding its presence in frontier technologies tied to healthcare and life sciences.
The funding round includes backing from Thrive Capital, Alphabet, GV, Temasek, CapitalG, the UK Sovereign AI Fund, and MGX.
The fresh capital will be used to strengthen its AI drug design engine, scale operations internationally, expand hiring efforts, and advance its therapeutic development pipeline.
The investment places MGX inside one of the fastest-growing segments of the AI economy, where machine learning systems are increasingly being applied to pharmaceutical research, molecular analysis, and drug development.
UAE Broadens AI Investment Strategy
MGX’s participation also reflects how Abu Dhabi’s AI ambitions are evolving beyond traditional computing infrastructure and into applied scientific technologies with long-term economic and healthcare implications.
While many global AI investments over the past two years have focused on data centers, chips, cloud systems, and large language models, healthcare has emerged as another strategic frontier for governments and institutional investors looking to secure exposure to next-generation industries.
The Isomorphic Labs investment gives MGX a foothold in AI-driven biotechnology at a time when pharmaceutical companies and research institutions are accelerating efforts to integrate machine learning into drug discovery workflows.
The move aligns with the UAE’s broader ambitions to position itself as a global technology and innovation hub with a growing role in advanced scientific sectors beyond digital infrastructure.
Isomorphic Labs Scales Its AI Drug Design Platform
Founded in 2021, Isomorphic Labs was created to apply artificial intelligence to the complex process of designing and developing new medicines.
The company said the latest funding will help expand its AI drug design platform, scale operations globally, and advance its therapeutic development programs.
Isomorphic Labs has drawn international attention through its connection to AlphaFold, the AI system developed by Google DeepMind that became widely recognized for predicting protein structures with high accuracy.
The company is now attempting to extend those AI capabilities into broader pharmaceutical research by using machine learning models to help identify and design potential drug candidates more efficiently.
Sir Demis Hassabis, Founder and CEO, said: "This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development. Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease."
The company added that the funding will also support hiring across artificial intelligence, engineering, drug design, and clinical development functions.
Growing Competition Around AI Healthcare Innovation
The investment comes as competition intensifies globally around the use of artificial intelligence in healthcare and biotechnology.
Technology companies, pharmaceutical firms, and sovereign-backed investment groups are increasingly targeting AI systems capable of improving research efficiency, accelerating discovery timelines, and reducing development costs associated with bringing new treatments to market.
Industry interest has grown particularly around AI models capable of analyzing biological structures, predicting molecular interactions, and assisting researchers during early-stage drug development.
Gulf investors such as MGX increasingly view these technologies not only as financial opportunities, but also as strategic exposure to industries expected to shape future healthcare systems and scientific research ecosystems.
The UAE has steadily increased its investments in artificial intelligence through partnerships, research initiatives, and sovereign-backed capital platforms aimed at securing influence in emerging technologies.
MGX itself has rapidly become one of the region’s most closely watched AI-focused investment firms as Abu Dhabi expands its role within the global AI landscape.
The Isomorphic Labs deal also highlights the growing convergence between artificial intelligence and biotechnology, a sector many analysts believe could become one of the most commercially significant applications of AI over the next decade.
Unlike consumer-focused AI products, drug discovery systems require extensive scientific validation, large-scale computing resources, and highly specialized research teams, making the sector particularly capital intensive.
That environment has created strong interest from large institutional investors capable of supporting long-term technology development cycles.
